Licensing opportunity
Swedish biotech Biovitrum said it has successfully completed phase I clinical studies of BVT.74316 and is now looking to outl-icense the product for onward development.
The compound, a 5-HT6 receptor antagonist for the treatment of obesity, controls food intake by stimulating the sense of satiety in the brain.
The phase I trial to test safety and tolerability in escalating single-dose and repeated-dose administration started in August 2006. In total, 98 healthy volunteers participated in the study. A safe and tolerable dose has been identified.
Biovitrum says the project falls outside the company’s new business focus and BVT.74316 is available for out-licensing
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
